ZVRA vs. PAAS

Last updated Jul 11, 2026

ZVRA (Zevra Therapeutics Inc.) and PAAS (Pan American Silver Corp.) are both stocks. ZVRA operates in Biotechnology (Healthcare), while PAAS operates in Silver (Basic Materials). Over the past 10 years, ZVRA returned -14.94%/yr vs 10.72%/yr for PAAS. At a 0.10 correlation, their price movements are largely independent.

Performance

ZVRA vs. PAAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zevra Therapeutics Inc. (ZVRA) and Pan American Silver Corp. (PAAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ZVRA achieves a 49.00% return, which is significantly higher than PAAS's -15.21% return. Over the past 10 years, ZVRA has underperformed PAAS with an annualized return of -14.94%, while PAAS has yielded a comparatively higher 10.72% annualized return.

ZVRA

• 1D: -4.23%
• 1M: 2.93%
• 6M: 57.24%
• YTD: 49.00%
• 1Y: 6.54%
• 3Y*: 40.34%
• 5Y*: 0.06%
• 10Y*: -14.94%

PAAS

• 1D: -1.02%
• 1M: -6.15%
• 6M: -19.06%
• YTD: -15.21%
• 1Y: 45.94%
• 3Y*: 45.73%
• 5Y*: 11.13%
• 10Y*: 10.72%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ZVRA vs. PAAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ZVRA Zevra Therapeutics Inc.	49.00%	7.43%	27.33%	42.70%	-47.30%	-22.23%	84.70%	-78.71%	-56.05%	37.29%
PAAS Pan American Silver Corp.	-15.21%	160.40%	26.61%	2.50%	-33.00%	-26.78%	46.88%	63.86%	-5.30%	3.86%

Correlation

The correlation between ZVRA and PAAS is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.12
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.15
Correlation (10Y) Calculated over the trailing 10-year period	0.10
Correlation (All Time) Calculated using the full available price history since Apr 16, 2015	0.10

Fundamentals

Market Cap ZVRA : $789.19M PAAS : $18.40B
EPS ZVRA : $2.15 PAAS : $3.12
PE Ratio ZVRA : 6.21 PAAS : 13.98
PS Ratio ZVRA : 6.31 PAAS : 4.43
PB Ratio ZVRA : 3.91 PAAS : 2.51
Total Revenue (TTM) ZVRA : $122.29M PAAS : $4.02B
Gross Profit (TTM) ZVRA : $104.94M PAAS : $1.76B
EBITDA (TTM) ZVRA : $149.15M PAAS : $2.14B

Return for Risk

ZVRA vs. PAAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZVRA

ZVRA Risk / Return Rank: 52
ZVRA Sharpe Ratio Rank: 53
ZVRA Sortino Ratio Rank: 52
ZVRA Omega Ratio Rank: 52
ZVRA Calmar Ratio Rank: 53
ZVRA Martin Ratio Rank: 51

PAAS

PAAS Risk / Return Rank: 71
PAAS Sharpe Ratio Rank: 74
PAAS Sortino Ratio Rank: 70
PAAS Omega Ratio Rank: 69
PAAS Calmar Ratio Rank: 71
PAAS Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZVRA vs. PAAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Pan American Silver Corp. (PAAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ZVRA	PAAS	Difference
Sharpe ratio: Return per unit of total volatility	0.18	0.91	-0.73
Sortino ratio: Return per unit of downside risk	0.73	1.47	-0.74
Omega ratio: Gain probability vs. loss probability	1.09	1.19	-0.10
Calmar ratio: Return relative to maximum drawdown	0.26	1.36	-1.10
Martin ratio: Return relative to average drawdown	0.45	3.33	-2.88

ZVRA vs. PAAS - Sharpe Ratio Comparison

The current ZVRA Sharpe Ratio is 0.18, which is lower than the PAAS Sharpe Ratio of 0.91. The chart below compares the historical Sharpe Ratios of ZVRA and PAAS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ZVRA vs. PAAS - Drawdown Comparison

The maximum ZVRA drawdown since its inception was -99.27%, which is greater than PAAS's maximum drawdown of -85.10%. Use the drawdown chart below to compare losses from any high point for ZVRA and PAAS.

Drawdown Indicators

	ZVRA	PAAS	Difference
Max Drawdown Largest peak-to-trough decline	-99.27%	-85.10%	-14.17%
Max Drawdown (1Y) Largest decline over 1 year	-43.47%	-37.62%	-5.85%
Max Drawdown (3Y) Largest decline over 3 years	-43.47%	-37.62%	-5.85%
Max Drawdown (5Y) Largest decline over 5 years	-66.94%	-57.39%	-9.55%
Max Drawdown (10Y) Largest decline over 10 years	-97.85%	-66.74%	-31.11%
Current Drawdown Current decline from peak	-96.47%	-36.06%	-60.41%
Average Drawdown Average peak-to-trough decline	-86.47%	-41.62%	-44.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.89%	15.33%	+9.56%

Volatility

ZVRA vs. PAAS - Volatility Comparison

The current volatility for Zevra Therapeutics Inc. (ZVRA) is 12.44%, while Pan American Silver Corp. (PAAS) has a volatility of 15.22%. This indicates that ZVRA experiences smaller price fluctuations and is considered to be less risky than PAAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ZVRA	PAAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.44%	15.22%	-2.78%
Volatility (6M) Calculated over the trailing 6-month period	40.65%	44.86%	-4.21%
Volatility (1Y) Calculated over the trailing 1-year period	61.17%	56.23%	+4.94%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.33%	48.19%	+12.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.82%	49.60%	+31.22%

Dividends

ZVRA vs. PAAS - Dividend Comparison

ZVRA has not paid dividends to shareholders, while PAAS's dividend yield for the trailing twelve months is around 1.42%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
PAAS Pan American Silver Corp.	1.42%	0.89%	1.98%	2.45%	2.75%	1.36%	0.64%	0.59%	0.96%	0.64%	0.33%	4.23%
ZVRA Zevra Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both ZVRA and PAAS in my portfolio?

ZVRA and PAAS have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ZVRA or PAAS?

PAAS has higher volatility (15.22%) compared to ZVRA (12.44%). In terms of maximum drawdown, ZVRA dropped -99.27% vs PAAS's -85.10%.

Which has better risk-adjusted returns?

PAAS currently has the higher Sharpe Ratio (0.91 vs 0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.